Opendata, web and dolomites


Translation and Commercialization of a QSOX1-inhibitory Antibody Targeting the Tumor Microenvironment in Breast Cancer

Total Cost €


EC-Contrib. €






 CONQR project word cloud

Explore the words cloud of the CONQR project. It provides you a very rough idea of what is the project "CONQR" about.

psychological    applicable    global    oophorectomy    metastasis    brca1    remodeling    therapeutic    unquantifiable    recommended    model    therapeutics    90    relapse    monoclonal    adenocarcinomas    penetration    deaths    negative    gene    preventive    young    metastases    drug    indications    stiffening    promise    mutations    inhibition    revolutionizing    position    discovery    migration    plan    imposes    primary    licensing    showed    treatment    stress    cancer    tumor    experiments    mastectomy    physical    extracellular    tnbc    breast    therapies    significantly    mice    explore    oncology    aggressive    majority    points    radiation    agent    commercialization    discoveries    reduce    risk    families    added    women    outcome    cell    worldwide    societal    qsox1    chemotherapy    pancreatic    counteracts    entering    patient    market    ecm    efficacy    benefit    cancers    reagent    enzyme    prevents    made    demand    lung    inhibitory    inhibitor    chemotherapies    standard    triple    matrix    antibody    secreted    perform    intended    preclinical    conqr    regimen    adhesion    found    continuing    mothers   

Project "CONQR" data sheet

The following table provides information about the project.


Organization address
address: HERZL STREET 234
postcode: 7610001

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 149˙998 €
 EC max contribution 149˙998 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2020-05-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WEIZMANN INSTITUTE OF SCIENCE IL (REHOVOT) coordinator 149˙998.00


 Project objective

The high number of cancer cases worldwide points to the large global demand for therapeutics for adenocarcinomas (the majority of lung, breast, and pancreatic cancers). Cancer metastases cause more than 90% of cancer patient deaths. There is thus great need to develop more targeted cancer therapies, as well as therapies that enhance the delivery and penetration of chemotherapies to reduce side effects and increase efficacy. A specific societal need is improved therapies for triple-negative breast cancer (TNBC), to which the targeted therapies developed for other breast cancers are not applicable. TNBC treatment, particularly for women with BRCA1 gene mutations, typically involves aggressive chemotherapy, mastectomy, and radiation treatment, with preventive oophorectomy also recommended. The physical and psychological impact of this regimen on young mothers and their families is unquantifiable, and the risk of relapse imposes continuing psychological stress.

We have made a revolutionizing discovery that significantly controlled cancer cell adhesion, cell migration, primary tumor growth, and metastasis. We found that inhibition of the secreted enzyme QSOX1 by a monoclonal antibody inhibitor counteracts extracellular matrix ECM matrix stiffening and prevents tumor cell adhesion and migration. The QSOX1 inhibitor showed an added benefit in controlling primary tumor growth and metastasis when provided together with standard chemotherapy in a TNBC model in mice. The antibody drug we are developing based on these exciting discoveries has great promise for commercialization as a new therapeutic agent for TNBC and for other oncology indications.

The goal of the CONQR project is to perform key preclinical experiments and explore market entering opportunities for commercialization of a novel QSOX1-inhibitory reagent against ECM remodeling in cancer. The intended outcome will be a development and commercialization plan to best position the product for out-licensing.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CONQR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CONQR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  


Precision medicine in traumatic brain injury using individual neurosteroid response

Read More  


RNA regulation during viral infection

Read More